Rimegepant ni molekile ntoya inhibitori yacalcitoninreseptor ya gene ifitanye isano na peptide (CGRP) ihagarika ibikorwa bya CGRP, vasodilator ikomeye ikeka ko igira uruhare mukubabara umutwe wa migraine.Rimegepant yemerewe kuvura ibitero bikaze bya migraine.Mu bigeragezo byo kwa muganga, rimegepant muri rusange yihanganiraga gusa hamwe na gake cyane ya serumu yinzibacyuho ya aminotransferase mugihe cyo kuvura kandi nta makuru yerekana ko yakomeretse umwijima.

Rimegepant ni umunwa urwanya reseptor ya CGRP yakozwe na Biohaven Pharmaceuticals.Yakiriye FDA ku ya 27 Gashyantare 2020 yo kuvura indwara ya migraine ikaze.Mugihe ababyeyi benshi barwanya CGRP hamwe niyakirwa ryabo bemerewe kuvura migraine (urugero: erenumab], [fremanezumab], [galcanezumab]), rimegepant na [ubrogepant] ni bo bonyine bagize umuryango wa "gepants" imiti isigaye mu iterambere, hamwe na CGRP yonyine barwanya bioavailable yo mu kanwa.Ubu buryo bwo kuvura migraine burimo kuvura gukuramo inda hamwe na "triptans", nka [sumatriptan], ariko iyi miti irabujijwe ku barwayi bafite indwara zifata ubwonko n'ubwonko bw'imitsi mbere na mbere bitewe na vasoconstrictive.Kurwanya inzira ya CGRP byahindutse intego ishimishije yo kuvura migraine kuko, bitandukanye na triptans, umunwa wa CGRP ntiwigeze ubona imitekerereze ya vasoconstrictive bityo ukaba ufite umutekano mukoresha kubarwayi bafite imiti ivura imiti isanzwe.

Rimegepant ni aCalcitoninGene ifitanye isano na Peptide Receptor Antagonist.Uburyo bwibikorwa bya rimegepant ni nka aCalcitoninGene ifitanye isano na Peptide Receptor Antagonist.